Keywords: AstraZeneca, Naloxegol, Pain, OIC, Adverse events
Encouraging results for AstraZeneca's naloxegol in OIC
Article | 26 February 2013
Anglo-Swedish drug major AstraZeneca (LSE: AZN) has announced high-level results from KODIAC-08, an open-label, randomized, 52-week, long-term safety trial of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
